What age do you need to be to use Wegovy in the UK?

Is there a minimum age for Wegovy, and why does it matter?

Yes. Wegovy is licensed for adults aged 18 and over in the UK. Below that threshold the medicine is not approved, and no regulated UK pharmacy should dispense it to someone younger. That position is clear in the NHS guidance on semaglutide and in the product's Summary of Product Characteristics.

The reasoning is straightforward: the clinical trials that underpinned the licence recruited adults. STEP 1, the landmark 68-week trial published in the New England Journal of Medicine, enrolled adults with obesity or excess weight and at least one weight-related condition, and the safety and effectiveness data the MHRA relied on comes from that population. Extrapolating to younger patients requires separate evidence, evidence that doesn't yet exist for Wegovy in this form.

A common misconception is that if the BMI criteria are met, almost anyone can be considered. That's not quite right. Regulatory licensing is a hard floor. Hitting a particular BMI at 16 does not make Wegovy an option; a prescriber cannot and should not work around the age limit, regardless of clinical need.

There is a separate, sometimes confused, point about semaglutide in diabetes contexts, but those involve different products and different licences. For weight management, 18 is the threshold. Full stop.

Does Wegovy have an upper age limit?

The short answer is no. There is no maximum age written into Wegovy's UK licence, and NICE's appraisal of semaglutide for weight management (TA875) does not impose one either.

That said, age still matters clinically. Prescribers look more carefully at older adults because the risk profile shifts. Side effects like nausea, vomiting and reduced appetite (common in the first weeks of treatment) can carry greater consequences for someone in their 70s or 80s if they lead to dehydration, falls or rapid muscle loss. Interactions with other medicines become more likely simply because older patients tend to take more of them. Kidney function, which can quietly decline with age, affects how well the body handles the medicine and any GI illness that comes with dose escalation.

None of this means Wegovy is off the table for older adults. Many people in their 50s, 60s and beyond use it safely and effectively. It means the prescriber's review is more thorough, not that the answer is automatically no. At nume, sorry, at nume, every consultation is read personally by a GPhC-registered Independent Prescriber who considers exactly those factors before making a clinical decision.

If you want to compare how age considerations look across semaglutide's different licensed uses, the broader semaglutide and age guidance page explores that in more detail.

How does age interact with the BMI eligibility criteria?

Wegovy's weight-management licence applies when BMI is 30 or above, or when it sits between 27 and 29.9 alongside at least one weight-related condition such as high blood pressure, raised cholesterol or type 2 diabetes. Lower thresholds apply for some ethnic backgrounds under UK clinical guidance. Age does not change those BMI numbers, but it does shape how the prescriber interprets what they see.

For younger adults at the lower end of the BMI range with a single comorbidity, a prescriber might want to understand more about lifestyle context and previous attempts at weight management. For older adults with the same BMI profile, they might weigh frailty, cardiovascular history or existing prescriptions differently. The numbers are a starting point; the clinical conversation is where individual suitability gets resolved.

NICE's guidance on semaglutide (TA875) also specifies that treatment should be reviewed if less than five percent of body weight has been lost after six months at the maintenance dose. That review applies regardless of age.

Costs, and what a private prescription actually covers, are worth understanding too. Our Wegovy price comparison page sets out what to look for when comparing providers, including what should always be included in a transparent price.

Are there other eligibility questions linked to age worth knowing about?

A few come up regularly. Pregnancy: Wegovy is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. Women of childbearing age should discuss contraception with their prescriber before starting, because the medicine may reduce the effectiveness of the oral contraceptive pill during dose changes. For tirzepatide users there is specific guidance about adding a barrier method during the first four weeks of treatment and after each dose increase; the MHRA has issued similar general advice for GLP-1 medicines as a category.

There is also a question about facial changes that sometimes surfaces in discussions about older adults on GLP-1 medicines. The concern about Wegovy and facial ageing is a real one in the sense that rapid weight loss from any cause can affect facial volume. It is worth reading about separately rather than letting it go unexamined.

For those who want a clear summary of the full age range covered by the licence and how it is interpreted in practice, our pages on Wegovy's age range and the Wegovy age limit go into further detail. Our guide to what age you can take Wegovy also addresses some of the more specific scenarios patients ask about.

If you have questions about whether you are a suitable candidate, our prescribers are the right people to ask. Speak to our prescribers through a free consultation, there is no obligation, and every response is a personal clinical review, not an automated reply.